Stockwinners Market Radar for July 31, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Cathie Wood's ARK Investment bought 121.4K shares of Pinterest today

19:36 EDT China's Center for Drug Evaluation accepts Astellas' BLA for zolbetuximab - Astellas Pharma "announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted the Biologics License Application for zolbetuximab, a first-in-class investigational Claudin 18.2-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in China for these patients. The BLA is based on results from the Phase 3 GLOW and SPOTLIGHT clinical trials. The GLOW study evaluated zolbetuximab plus CAPOX compared to placebo plus CAPOX. In the GLOW study, 145 patients were randomized in mainland China. The SPOTLIGHT study evaluated zolbetuximab plus mFOLFOX6 compared to placebo plus mFOLFOX6. In the SPOTLIGHT study, 36 patients were randomized in mainland China."

18:43 EDT Lithia & Driveway CFO Miller sells 2,000 common shares - In a regulatory filing, Lithia & Driveway CFO Tina Miller disclosed the sale of 2,000 common shares of the company on July 31 at a price of $310 per share.

18:09 EDT Eve Holding names Johann Bordais as new CEO - Eve Air Mobility announced that its Board of Directors has appointed Johann Bordais, current President and CEO of Embraer Services & Support, as Chief Executive Officer to be effective on September 1, 2023. Eve's co-CEOs, Andre Stein and Jerry DeMuro, will remain at Eve with new roles.

17:31 EDT Arista Networks CEO says aiming for at least double-digit growth next year - In a Q/A session of the company's earnings call, CEO Jayshee Ullal said: "Rest assured that we are aiming for at least double digits (growth) next year."

17:22 EDT Northrop Grumman awarded $387.81M Navy contract modification - Northrop Grumman was awarded a $387.81M fixed-price incentive, cost-plus-fixed-fee, firm-fixed-price modification to a previously awarded contract. This modification adds scope to provide non-recurring engineering efforts in support of the production of three unique configuration E-2D Advanced Hawkeye for the Government of France. Work is expected to be completed in December 2027. Foreign Military Sales customer funds in the amount of $330.27M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:21 EDT Oshkosh awarded $201.52M Army contract modification - Oshkosh was awarded a $201.52M modification to a contract for the Family of Medium Trucks. Work will be performed in Oshkosh, Wisconsin, with an estimated completion date of July 31, 2025. FY23 other procurement, Army funds; and Ukraine Security Assistance Initiative funds in the amount of $201.52M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:19 EDT Whirlpool CEO sells $2.86M in common stock - In a regulatory filing, Whirlpool disclosed that its CEO Marc Bitzer sold 20K shares of common stock on July 28th in a total transaction size of $2.86M.

17:15 EDT Harmonic falls 14% to $12.80 after Q2 earnings miss, below-consensus guidance

17:11 EDT Rite Aid chief digital and technology officer Mennen to leave company - According to a regulatory filing, on July 28, 2023, Justin Mennen, the EVP and Chief Digital and Technology Officer of Rite Aid Corporation, ceased to be employed by the company, effective immediately. In connection with such termination of employment, the Company entered into a separation agreement and release with Mr. Mennen pursuant to which: Mr. Mennen waived his rights to severance benefits under his employment agreement with the Company dated December 7, 2018, and amended as of November 6, 2019, the Company agreed to pay Mr. Mennen $900,000 in a lump sum in consideration for the waiver and general release of claims and Mennen retained his right to a retention payment of $750,000 pursuant to the letter agreement between the Company and Mr. Mennen dated April 28, 2023, as previously filed as Exhibit 10.37 to its Quarterly Report on Form 10-Q on July 11, 2023.

17:07 EDT Archrock reports Q2 EPS 16c, consensus 14c - Reports Q2 revenue $247.54M, consensus $241.77M. "Exceptional execution drove Archrock's outstanding second quarter performance," said Brad Childers, Archrock's president and CEO. "With unwavering customer demand for our services, we achieved another all-time high fleet utilization of 95% at quarter end and record monthly revenue per horsepower in the quarter. Higher pricing and our continued focus on cost management drove an increase in our contract operations gross margin percentage of 450 basis points compared to the first quarter of 2023. In aftermarket services, we delivered year-over-year gross margin growth of more than 40%, the result of encouraging outsourcing trends for equipment maintenance as well as meaningful price increases."

17:01 EDT Fresh Vine receives NYSE American notice - Fresh Vine Wine announced that it received a Notice on July 27, 2023 from the NYSE American LLC stating that the Company was not in compliance with the continued listing standards as set forth in Section 803B of the NYSE American Company Guide, relating to the composition of its audit committee. On July 19, 2023, the Company's Board of Directors appointed Michael Pruitt, the Non-Executive Chair of the Company's Board of Directors, to serve as Interim Chief Executive Officer. As a result of such interim appointment, Mr. Pruitt ceased serving as one of two members of the Company's audit committee because he is not considered an independent director under Section 803A of the NYSE American Company Guide while serving as Chief Executive Officer. As a result, on July 27, 2023, the Company received the Notice, indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 801(h) and 803B(2)(c) of the NYSE American Company Guide because its audit committee was not comprised of at least two members.

16:41 EDT Trupanion expands access through hospital group partnerships - Trupanion announced that following a series of newly signed agreements, it now has partnerships with more than 60 of the 100+ multilocation veterinary hospital groups in North America. In signing several preferred partners in 2023, more Trupanion members than ever before can have their pets cared for without the burden of filing a claim for reimbursement.

16:34 EDT DBV Technologies gets FDA design feedback on Viaskin peanut safety study - DBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT or Characterization of the Optimal Management of Food Allergy Relief and Treatment, Toddlers and COMFORT Children supplemental safety studies in 1 - 3-year-olds and 4 - 7-year-olds, respectively, with a peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28. T

16:28 EDT Emergent BioSolutions awarded 10-year $121M BARDA contract - Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness and Response, or ASPR, within the U.S. Department of Health and Human Services, or HHS, valued at up to a maximum of $704M, for advanced development, manufacturing scale-up, and procurement of Ebanga, a licensed treatment for Ebola virus disease, or EVD. The 10-year contract consists of a base period of performance with two option periods for advanced development valued at approximately $121M, and option periods for procurement of Ebanga treatment over five years valued at up to $583M. If all option periods are exercised, the total contract value will be valued at up to approximately $704M. Under the terms of the contract, Emergent will complete activities to advance the development of Ebanga treatment through post-licensure commitments, including the transfer of technology as part of manufacturing scale-up, submission of a supplemental Biologics License Application to the FDA, and completion of stability studies.

16:27 EDT ZoomInfo falls 20% to $20.29 after Q2 results, FY23 revenue guidance cut

16:25 EDT QuantumScape names Siva Sivaram president - QuantumScape (QS) announced the appointment of Dr. Siva Sivaram, President of Western Digital Corp. (WDC) and a veteran of the semiconductor and data storage industries, to the newly created role of President. In this position, Dr. Sivaram will oversee QuantumScape's technology and manufacturing groups as the company ramps up its transition from R&D to production. Just last week, QuantumScape announced it shipped updated prototype unit cells to automotive customers, locked in on the ~5 amp-hour QSE-5 cell as its target first commercial product, revealed it was working with a prospective launch customer on QSE-5, and completed equipment installation for its new fast separator production process. "We're thrilled to have Siva join the team," said QuantumScape CEO Jagdeep Singh. "There are very few people in the world who have run businesses with extremely high production volumes that also involve complex technologies and sophisticated manufacturing processes, and he is one of them. I'm delighted to work with him to help bring our vision to reality."

16:22 EDT IBM names Michael Miebach to board of directors - The IBM (IBM) board of directors has elected Michael Miebach to the board, effective October 30. Michael Miebach is the CEO of Mastercard (MA) and a member of its board of directors.

16:20 EDT Dynatrace to acquire Rookout - The company states: "Dynatrace announced it has signed a definitive agreement to acquire Rookout, a provider of enterprise-ready and privacy-aware solutions that enable developers to quickly troubleshoot and debug actively running code in Kubernetes-hosted cloud-native applications. The addition of Rookout to the Dynatrace(R) platform will help developers accelerate innovation and delivery of flawless and secure releases."

16:18 EDT ZoomInfo board approves new buyback for up to $500M

16:16 EDT Diamondback Energy raises FY23 oil production view to 440 MBOE/d from 435 MBO - The second quarter of 2023 was characterized by volume outperformance, reduced operating and administrative expenses, decreased net debt, additional non-core divestitures and another increase to our base dividend. Further, we have line of sight to significant capex reductions through the remainder of the year, which will result in higher expected Free Cash Flow at current commodity prices. To summarize, we continue to execute across all facets of our business model. Production: Diamondback continued to execute and exceed expectations in the second quarter, with both oil and total production above the high end of our second quarter guidance ranges. As a result of this year-to-date outperformance and our continued confidence in the forward outlook, we are increasing our full year oil and total production estimates to the high end of their respective annual ranges. The midpoint of annual daily oil production moves to 261 MBO/d from 259 MBO/d, while the midpoint of annual total daily production moves to 440 MBOE/d from 435 MBOE/d. Oil production is expected to grow slightly in the second half of the year, with third quarter oil production projected to be 262 - 265 MBO/d . We anticipate we will continue to grow oil production organically at a low single digit annual pace next year with a similar level of activity to this year. This is primarily a result of the quality of the acreage we are developing on a large scale in the Midland Basin, combined with a high mineral interest across the development plan.

16:14 EDT Woodward up 9.5% after reporting Q3 earnings, raising FY23 guidance

16:14 EDT Golden Entertainment declares $2.00 per share special dividend - The one-time cash dividend is payable on August 25, 2023 to stockholders of record as of August 11, 2023.

16:05 EDT Fluor-led JV selected for I-35 NEX South project valued around $700M - Fluor announced that Lone Star Constructors, a Fluor-led joint venture, was selected as the design, construction and capital maintenance contractor for the Interstate 35 Northeast Expansion South Project in San Antonio, Texas, by the Texas Department of Transportation. Fluor expects to recognize the approximately $700M contract in the second quarter of 2023. Construction is scheduled to begin in 2024 and be completed in 2028.

16:01 EDT Palantir selected by DISA to automate spectrum coordination workflows - Palantir Technologies announced that it was selected by the Defense Information Systems Agency to support coordination between federal and commercial licensees of the 3450 - 3550 MHz spectrum band. Palantir will provide its software platform to enable end-to-end automation that will enhance coordination between the Department of Defense and commercial spectrum licensees for shared use of the 3450-3550 MHz band within cooperative planning area and periodic use area coordination zone boundaries.

14:28 EDT Teamsters say served legal notice Yellow ceasing operations, filing bankruptcy - The Teamsters Union was served legal notice today that Yellow Corp. is ceasing operations and filing for bankruptcy, the union announced. "Today's news is unfortunate but not surprising. Yellow has historically proven that it could not manage itself despite billions of dollars in worker concessions and hundreds of millions in bailout funding from the federal government. This is a sad day for workers and the American freight industry," said Teamsters General President Sean M. O'Brien. Reference Link

13:59 EDT EEOC sues HCA Healthcare for alleged discrimination and retaliation - HCA Healthcare, and its divisions Tennessee Healthcare Management, Inc. and GME Overhead, a for-profit corporation headquartered in Nashville, providing graduate medical education in over 2,300 health care facilities, violated federal law by refusing to promote an employee because of his age, race and national origin, the U.S. Equal Employment Opportunity Commission, or EEOC, charged in a lawsuit filed today, the Commission announced. The EEOC filed suit in U.S. District Court for the Middle District of Tennessee, Nashville Division, after first attempting to reach a pre-litigation settlement through its conciliation process. The EEOC seeks injunctive relief prohibiting the defendants from discriminating against their employees because of age, race, and national origin, and from retaliating against employees in the future, as well as monetary relief, the EEOC stated. Reference Link

13:25 EDT Coinbase says systems 'currently experiencing issues' - Coinbase said via its website, "Our systems are currently experiencing issues. While we work on a fix, your funds remain secure."

13:08 EDT GSK reports FDA grants expanded approval of Jemperli - GSK plc announced that the U.S. Food and Drug Administration has approved Jemperli in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, or dMMR, as determined by an FDA-approved test, or microsatellite instability-high, or MSI-H. The supplemental Biologics License Application, or sBLA, supporting this new indication received Priority Review and was approved ahead of the Prescription Drug User Fee Act action date, the company noted. Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: "Today's expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression. In the RUBY trial, Jemperli plus chemotherapy demonstrated a 71% reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit. These results and today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

12:29 EDT Tyra Biosciences granted orphan status for achondroplasia treatment - The FDA granted Tyra Biosciences orphan status for its treatment of achondroplasia. Reference Link

12:00 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -7.8% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -7.8%, or -51c to $6.07.

12:00 EDT XPeng falls -14.1% - XPeng is down -14.1%, or -$3.30 to $20.09.

12:00 EDT Archer Aviation rises 29.4% - Archer Aviation is up 29.4%, or $1.40 to $6.18.

11:48 EDT Air Products to increase production capacity at Manatee, Florida facility - Air Products will be making a significant investment to meet industry demand with increased winding capacity at its LNG equipment manufacturing facility located in Port Manatee, Florida. Air Products expects that this increase in capacity, coupled with new proprietary innovations in fabrication methods, will enable Air Products to improve equipment delivery schedules. Winding is a fabrication process for the internal components of coil-wound heat exchangers in which layers of tubes are wound around a central mandrel. This investment will increase Air Products' manufacturing capacity by almost 20 percent. This is on top of a previous expansion completed in 2019 that increased the facility's original capacity by 60 percent. Known for reliability and efficiency, Air Products' liquefaction process technologies and equipment are used to produce a majority of the total worldwide LNG.

11:39 EDT Senator Sanders, others urge DOJ to bring suits against ExxonMobil, Shell - Senator Bernie Sanders said in a tweet that, "Today, @SenWarren, @SenMarkey, @SenJeffMerkley and I sent a letter to Attorney General Garland urging the DOJ to bring lawsuits against the fossil fuel industry for its longstanding campaign to mislead consumers and discredit climate science in pursuit of massive profits. and other fossil fuel companies for their longstanding campaign to mislead consumers and discredit climate science in pursuit of massive profits." Sanders also shared two pictures of the letter that reads in part, "We write to strongly urge the Department of Justice to bring suits against the fossil fuel industry for its longstanding and carefully coordinated campaign to mislead consumers and discredit climate science in pursuit of massive profits. The actions of ExxonMobil, Shell, and potentially other fossil fuel companies represent a clear violation of federal racketeering laws, truth in advertising laws, consumer protection laws, and potentially other laws, and the Department must act swiftly to hold them accountable for their unlawful actions." Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Shell (SHEL) and TotalEnergies (TTE).Reference Link

11:05 EDT Steel Dynamics signs RPPA with NextEra Energy subsidiary - Steel Dynamics (STLD) has signed a Renewable Product Purchase Agreement with a subsidiary of NextEra Energy Resources (NEE) for 308 megawatts of energy to be produced by a new wind farm project in Scurry County, Texas. The RPPA is the largest of its kind for the steel industry in North America. This project marks significant progress toward the company's decarbonization goals. Once operational, this wind farm project is expected to produce approximately 1.1 million MWh of electricity annually, equivalent to 16% of the company's steel mills' electricity usage in 2022, surpassing the company's 2025 goal of 10% renewable electricity and moving toward its 2030 goal of 30%. Additionally, this is expected to meaningfully contribute to the company's long-term reduction of Scope 2 greenhouse gas emissions intensity.

10:51 EDT CMC Metals intersects mineralization at Silverknife property - CMC Metals has intersected mineralization in the second hole drilled within the Silverknife prospect, north-central British Columbia. Mineralization has been observed in several intersections of limestones in the Kechika Formation and is characteristic of silver-lead-zinc "CRD style" mineralization. It comprises of manganese alteration, sphalerite, galena, and zincite. Examination of the core with XRF has also indicated the possible presence of manganese, other iron sulfides, zinc, lead, and possibly gold. Core is being prepared for assaying which will include testing for critical minerals such as germanium and gallium. The first hole intersected the contact between the sediments and the granite-granodiorite intrusive which is important as it indicates the possibility that the mineralization is resultant from the intrusion which provides the heat source for the movement of mineralized fluids into the overlying sediments. Approximately 700 meters of the proposed 3,000 meter drill program for the 2023 exploration season has been completed to date. The Silverknife property is located immediately west of the Silvertip Mine property owned by Coeur Mining. The Silvertip Mine is one of the highest-grade underground silver-lead-zinc deposits in the world. Mineralization in the area is known to be characteristic of carbonate replacement style deposits and recent modelling of the Silvertip deposit has postulated the possibility of mineralization occurring throughout the significant sedimentary package with thickness of up to 2,500 meters. Of interesting note is that Coeur also postulated on the prospectivity of other sediments deeper in the sedimentary package such as the Kechika Group as possible targets for "CRD" and critical minerals mineralization. CMC completed a gravity survey over the Silverknife Prospect which identified a significant gravity anomaly coincident with previous geophysical and geochemical anomalies. The Company is awaiting the geophysical report from Intelligent Exploration before providing any further comment. Plans are underway to continue drilling in the area to further define the extent of mineralization in the area of the prospect. The historic Silverknife Prospect which was subjected to drilling in the mid 1980's that identified significant CRD mineralization that was reported to remain open in several directions. 3-D modelling has shown that previous drilling on the Silverknife Prospect was conducted on the edge of the conductors and was in close proximity to the recently identified gravity anomaly. CMC has also completed two drill holes in close proximity to the gravity/conductivity anomaly just south of the Tootsee River and intersected granite-granodiorite intrusive rocks. No outcrops are observed in this area but immediately north of the intrusive and the Tootsee River, limestone sequences of the McDame Formation have been identified and are coincident with the gravity/conductivity anomaly. The presence of McDame limestones in close proximity to a heat source presents an ideal setting for CRD mineralization. Drilling north of the Tootsee River requires widening of existing trails in the area to permit accessibility by drilling equipment and work has begin on determining the most viable route to reach the exploration target area. This area will likely be targeted in the 2024 season as it is expected to take a couple of months to prepare the access road.

10:20 EDT Micromobility.com submits non-binding bid to acquire VanMoof - micromobility.com as submitted a non-binding bid to acquire VanMoof Amsterdam. The company said, "Micromobility's initial non-binding bid, demonstrating the company's strong commitment to its expansion in the micromobility market, was positively received. The company is now preparing to present its binding offer...Upon successful acquisition, Micromobility plans to leverage its advanced e-bike technology and successful subscription model to enhance the group's product offerings. The Company intends to continue investing in the e-bike segment, as it sees significant potential in this market in the coming years." The Company will release more information about the acquisition process as developments progress.

10:02 EDT Blackbaud announces strategic investment in AI startup Momentum - Blackbaud announced a strategic investment in Momentum, an AI-focused Blackbaud partner, graduate of Blackbaud's Social Good Startup tech accelerator program, and winner of Blackbaud's 2022 startup showcase. This investment in Momentum is one way the company is accelerating product delivery and focusing on the creation of AI capabilities embedded in Blackbaud solutions. With Momentum's integration with Blackbaud Raiser's Edge NXT, Blackbaud customers can optimize their fundraising and stewardship processes. Momentum, founded by behavioral scientists from Duke's Center for Advanced Hindsight, launched the first version of its solution in 2019. Key to Momentum's success is a focus on the use of AI to create fundraising tools that build lasting relationships between high impact charities and their donors. In its current release, the Momentum platform connects donor portfolios with automation and generative AI capabilities to deliver personalized first-draft communications and outreach recommendations directly to a fundraiser's email inbox. Customers using Momentum thus far have experienced a 400% increase in the number of personalized touchpoints their fundraisers could produce and an average of $60,000 per month in increased donations

10:00 EDT Gaotu Techedu falls -6.2% - Gaotu Techedu is down -6.2%, or -27c to $4.15.

10:00 EDT XPeng falls -12.7% - XPeng is down -12.7%, or -$2.96 to $20.43.

10:00 EDT New Relic rises 13.4% - New Relic is up 13.4%, or $9.95 to $84.00.

09:50 EDT MyMD Pharmaceuticals trading resumes

09:47 EDT QuantumScape falls -5.8% - QuantumScape is down -5.8%, or -77c to $12.50.

09:47 EDT XPeng falls -10.9% - XPeng is down -10.9%, or -$2.56 to $20.83.

09:47 EDT Sweetgreen rises 11.0% - Sweetgreen is up 11.0%, or $1.56 to $15.65.

09:46 EDT Fifth Wall Acquisition Corp III trading halted, volatility trading pause

09:36 EDT Knightscope signs contract with healthcare organization for K5 ASR service - Knightscope announced that a California based healthcare organization signed a new contract for its K5 Autonomous Security Robot service at a San Francisco Bay Area hospital.

09:34 EDT Navidea to appeal potential delisting from NYSE American Exchange - Navidea Biopharmaceuticals announced it is intending to appeal potential delisting from the NYSE American Exchange. "Although the traditional exchange has been a part of Navidea's history and may be in the future, our strategy and approach remains resolute in the face of change. The company's progress is clear, and the impact of the changes we have made will continue to move us forward. Navidea will continue to focus on using our Fix, Fund Propel approach, our strategic vision to advance Navidea's innovative technology to market, and the delivery of value to our stockholders," said Josh Wilson, Director.

09:33 EDT Biohaven says taldefgrobep alfa receives EU orphan drug designation for SMA - Biohaven announced that it received orphan medicinal product designation from the European Commission for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy, or SMA. Irfan Qureshi, MD, Chief Medical Officer, Biohaven commented, "We are delighted that the European Commission granted orphan drug designation for taldefgrobep alfa for the treatment of SMA. Children and adults living with SMA experience significant muscle weakness and functional impairments affecting their quality of daily life, and a substantial unmet medical need persists. We are excited about the potential for taldefgrobep alfa to improve the lives of patients and families affected by SMA."

09:24 EDT Insignia Systems receives shareholder approval for sale of marketing business - Insignia Systems announced that its shareholders approved its previously announced agreement to sell its in-store marketing business to an affiliate of Park Printing at the Company's annual meeting of shareholders held on July 27, 2023. The Company expects the sale to close after the market close as of August 3, 2023. Following completion of the sale, the Company will be focused on building a scalable non-bank lending platform, which purchases existing loans and/or originates and funds new loans. In connection with the sale of the in-store marketing business, the Company announced that Kristine Glancy, the Company's President and CEO, will be departing from the Company at the end of August 2023.

09:21 EDT Ra Medical Systems announces proposed name, ticker symbol change - Ra Medical Systems announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is expected to be August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unveiled shortly in conjunction with the name change. For now, investors can continue to visit www.ramed.com.

09:19 EDT US Antimony appoints Richard Isaak as CFO - United States Antimony announced the appointment of Richard Isaak as Senior Vice President and CFO. He succeeds Kelly Stopher who previously served as the Company's contract CFO. Mr. Stopher will remain as a consultant during the transition period. Rick served in several senior leadership roles including CFO, Chief Accounting Officer, Controller, Treasurer, and Head of Investor Relations at four different companies over 20 years including Panera Bread Company, Heritage Home Group, and Merric Millwork and Seating, and Catholic Charities.

09:16 EDT Aytu BioPharma enters exclusive agreement with Medomie Pharma - Aytu BioPharma and Medomie Pharma announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines. Medomie will seek local regulatory approvals and marketing authorizations for both Adzenys and Cotempla. This agreement represents Aytu's first international commercial agreement for Adzenys and Cotempla.

09:12 EDT MyMD Pharmaceuticals announces MYMD-1 met primary, secondary endpoints - MyMD Pharmaceuticals announced statistically significant topline results from its randomized Phase 2 study of oral TNF-a inhibitor, MYMD-1 in patients with chronic inflammation associated with sarcopenia, or age-related frailty. The study met its primary endpoints of significantly reducing chronic inflammatory markers in participants treated with MYMD-1. MYMD-1 has the potential to be the first drug approved by the FDA for sarcopenia, an age-related decline in physical function which leads to greater risk of hospitalization, disability, and death. The study met both of its primary endpoints, significantly reducing serum levels of three biomarkers, TNF-a, sTNFR1 and IL-6 and maintaining appropriate plasma concentrations and parameters in pharmacokinetic evaluations. The study also achieved all secondary endpoints related to safety and tolerability. There were no treatment-related adverse events, or AEs, or serious adverse events, or SAEs, over the course of the study. The Phase 2 multi-center double-blind, placebo controlled, randomized study was designed to investigate the efficacy, tolerability and pharmacokinetics of MYMD-1 in participants aged 65 years or older with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines. Patients in the study were dosed weekly with MYMD-1 or placebo over a 28-day period. The study consisted of four dosing cohorts versus placebo. Full results from the study will be presented or published at a later date to be determined. The company plans to initiate discussions with the FDA regarding a Phase 3 study of MYMD-1 in sarcopenia.

09:11 EDT Curtiss-Wright announces $250M U.S. Naval Defense contract - Curtiss-Wright Corporation announced that it has been awarded contracts valued in excess of $250M to provide propulsion valves, pumps and advanced instrumentation and control systems for the U.S. Navy's Virginia-class nuclear powered attack submarine, Columbia-class submarine and Ford-class aircraft carrier programs. The awards were received from Bechtel Plant Machinery BPMI and General Dynamics Electric Boat to support ship construction, spare parts and submarine back-fit procurements. "Curtiss-Wright is pleased to have been awarded these important naval defense contracts, building upon our long-standing relationship with the U.S. Nuclear Navy and reflecting our ongoing support of these critical naval defense platforms, which continue to receive strong Congressional support," said Lynn M. Bamford, Chair and CEO of Curtiss-Wright Corporation. "We look forward to delivering the most advanced, reliable and vital technologies and remain well-positioned to benefit from the continued expansion of our U.S. naval fleet."

09:10 EDT Point Biopharma, ITM expand global supply agreement for n.c.a. Lutetium-177 - ITM Isotope Technologies Munich and POINT Biopharma announced the expansion of their global supply agreements signed in 2020. The expanded agreement broadens the supply of ITM's non-carrier-added lutetium-177 to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT's development pipeline. Financial details of the agreement were not disclosed.

09:08 EDT Upwork announces OpenAI Experts on Upwork - Upwork announced OpenAI Experts on Upwork, giving OpenAI customers and other businesses direct access to trusted expert independent professionals deeply experienced in working with OpenAI technologies. Upwork and OpenAI co-designed the program to feature talent adept at working with the OpenAI API platform and to draw from the 250 unique AI skills available on Upwork, including GPT-4, Whisper and AI model integration. With Upwork's marketplace, OpenAI is already leveraging talent from the Upwork platform to support its own innovation and growth, and quickly saw value in helping its customers connect to talent on Upwork, leading to the new partnership. Together, the companies identified the most common use cases for OpenAI customers - like building applications powered by large language models, fine-tuning models and developing chatbots with responsible AI in mind - along with the key skills required for success. The two companies also formulated a pre-vetting process for identifying AI experts who appear as part of the program.

09:07 EDT ZOOZ Power to go public via merger with Keyarch Acquisition - ZOOZ Power and Keyarch Acquisition announced that they have entered into a business combination agreement and certain ancillary agreements related thereto. Following the closing of the transaction, ZOOZ is expected to be publicly listed on Nasdaq under the symbol "ZOOZ", and will remain listed on the Tel Aviv Stock Exchange. After the closing, the merged company will continue to be called ZOOZ Power Ltd. The closing is expected to occur in the fourth quarter of 2023 and is subject to applicable closing conditions, including receipt of ZOOZ and Keyarch shareholder and regulatory approvals and a minimum of $10M net cash at closing, along with other customary conditions. Transaction values ZOOZ immediately prior to the closing at an agreed equity value of up to $100M, which reflects $60M at closing and up to $40M of additional contingent consideration through issuance of Earnout Shares following the closing upon ZOOZ's achievement of the applicable earnout milestones as set forth in the Business Combination Agreement. The transaction is expected to provide a minimum of $10M in net proceeds from cash held in Keyarch's trust account and/or other sources.

09:03 EDT Bank7 increases dividend 31.25% to 21c - Bank7, the parent company of Oklahoma City-based Bank7, announced that its Board of Directors has declared an increase to its quarterly cash dividend to 21c per common share from the current 16c per common share. This dividend represents a 31.25% increase to the current dividend and is the fourth consecutive annual increase in BSVN's quarterly cash dividend. The dividend will be paid on October 10 to shareholders of record as of the close of business on September 26.

09:02 EDT Blue Water Biotech, Knipper Health partner to distribute samples to physicians - Blue Water Biotech announced an agreement with Knipper Health to manage the inventory and distribution of product samples to sales representatives for ENTADFI and ZONTIVITY. As part of Blue Water's product roll-out plans, Knipper Health will oversee sample inventory and ship samples on request to the sales force in the field. This will help to expedite physicians' initiation of therapy for their patients while increasing familiarity with the products.

08:57 EDT Washington Water Service receives approval from Washington commission - Washington Water Service has received approval from the Washington Utilities and Transportation Commission to increase annual revenues by $2.125 million, effective July 28, 2023, to reflect upgrades made to water system infrastructure and higher operating costs. Additionally, the Commission authorized funding-a portion of which is expected to be recovered in future years-for conservation programs, education, and outreach for the utility to help consumers use water more efficiently.

08:55 EDT MyMD Pharmaceuticals trading halted, news pending

08:53 EDT Mustang Bio amends, closes manufacturing partnership transaction with uBriGene - Mustang Bio amended its previously announced asset purchase agreement with uBriGene and closed the transaction under the terms of the amended asset purchase agreement. Per the terms of the amended agreement, at closing, uBriGene acquired all of Mustang's assets primarily relating to the manufacturing and production of cell and gene therapies for upfront consideration of $6 million in cash. Mustang's lease to the premises in Worcester, Massachusetts where its state-of-the-art clinical- and commercial-scale cell and gene therapy manufacturing facility is located did not transfer at closing because such transfer requires the consent of the landlord, which has requested additional time to consider the proposed transfer. An additional $5 million contingent payment will be payable to Mustang upon Mustang's raising $10 million in gross proceeds from equity raises following the closing of the transaction and completion of the assignment of Mustang's lease to uBriGene, which remains subject to landlord's approval. Unless and until the lease is transferred to uBriGene, Mustang will retain its facility lease and facility personnel, and will continue to occupy the leasehold premises and manufacture there its lead product candidate, MB-106. The amended asset purchase agreement provides that Mustang will continue to work with uBriGene to secure the assignment of its manufacturing facility lease, which would complete the transfer of its facility to uBriGene as originally planned. The Company and uBriGene expect to complete their filing of a joint voluntary notice to obtain clearance for the transaction from the U.S. Committee on Foreign Investment in the United States no later than August 31, 2023. It is expected that CFIUS may take up to 90 days to complete its review, after which Mustang's landlord has informed the Company that it will require an additional 30 days to review the request for consent to assign the lease. If, after 120 days from the date of closing, the lease has not transferred to uBriGene, uBriGene may request the parties use their best commercial efforts to negotiate in good faith a repurchase by Mustang of the transferred assets and assumed liabilities acquired on the date of closing. Under the terms of the amended asset purchase agreement, the lease of the facility and related contracts are to be transferred to uBriGene within three business days following receipt of the landlord's consent to the proposed lease transfer, and Mustang employees who support the transferred operations and have accepted offers of employment with uBriGene will become employees of uBriGene effective on the date that is 30 days following the completion of the lease transfer. At closing, Mustang and uBriGene also entered into a manufacturing services agreement, under which Mustang contracted uBriGene to manufacture Mustang's lead product candidates. This includes the manufacturing of MB-106, the Company's first-in-class CD20-targeted autologous CAR T therapy, for the ongoing multi-center Phase 1/2 trial in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. Pending the landlord's determination regarding transfer of the facility lease to uBriGene, Mustang and uBriGene also have entered into a second manufacturing services agreement, under which Mustang will serve as uBriGene's contract development and manufacturing provider and will continue to manufacture MB-106, as well as potentially other cell and gene therapies, in exchange for compensation to be equal to Mustang's operating costs associated with the performance of such services. The upfront proceeds from the transaction and recent reductions in operating expenses relating to Mustang's portfolio along with resource optimization are expected to extend the Company's cash runway into early 2024. The Worcester facility is a 27,000 square foot, cutting-edge cGMP facility supporting process development, manufacturing and analytical testing, designed with the flexibility to expand and support various cell and gene therapy production requirements and capacities. Upon transfer of the lease to uBriGene, Mustang's headquarters will relocate to 1 Mercantile Street, in Worcester, MA.

08:50 EDT AMMO CEO sees 'considerable progress in the quarters ahead' - AMMO issued a Letter to Shareholders from CEO Jared Smith, which read in part, "I am pleased to communicate directly with you as AMMO, Inc.'s new Chief Executive Officer and want to take this opportunity to share the many developments that have occurred over the past six months and the future we envision for AMMO and GunBroker.com. I would like to begin by acknowledging AMMO Inc.'s Executive Chairman Fred Wagenhals and thank him on behalf of our leadership team and Board members for his innumerable and invaluable contributions over the past seven years. I look forward to learning from his impeccable entrepreneurial instincts and drive. I would also like to acknowledge all of our employees for their hard work and our investors for their continued patience. To our employees: this change has not been easy and current market conditions have made this transition even tougher. We have a very bright future, and I believe our team is now aligned to execute on a set of principles and goals that will drive long term shareholder value. To our investors: I ask that you maintain your faith in AMMO's vision. We are now starting to execute on that vision while quickly making the changes necessary to win and maintain your confidence. We anticipate considerable progress in the quarters ahead through careful execution under three major categories: alignment and commitment from management; expansion of the reach and positioning of GunBroker.com; and enhancing our margins, operational prowess, and brand strength for our AMMO division...We are grateful for our shareholders' interest and support of AMMO and our singular goal remains that our long-term and supportive shareholders realize the full potential of these amazing businesses, which will be reflected in our future financial performance and the share price."

08:47 EDT HomeTrust Bank appoints Megan Pelletier as chief operations, people officer - HomeTrust Bancshares announced that Megan Pelletier, SPHR, has assumed the position of Executive Vice President, Chief Operations & People Officer effective today. In her new role, Pelletier will retain responsibility for Human Resources and assume responsibility for Deposit and Loan Operations and Project Management functions. In this capacity, Pelletier will oversee the Bank's teams of back-office professionals across five states to provide nimble, best-of-class service to the customers and communities served by HomeTrust. Pelletier's tenure with HomeTrust began in May 2022 when she joined the Bank as Chief People Officer.

08:46 EDT Cellebrite announces new capabilities for Cellebrite Guardian - Cellebrite DI announced new capabilities for Cellebrite Guardian, a leading SaaS-based evidence and workflow management solution for law enforcement agencies of all sizes. Cellebrite Guardian securely and transparently streamlines investigative digital forensic processes, enabling greater efficiency for law enforcement and investigative teams at scale, increasing case resolution and creating a verifiable- chain of custody for sharing digital evidence among examiners, investigators and prosecutors. Among the most impactful new advantages is "Simple Upload", a swift, intuitive, drag-and-drop uploader that allows investigators to quickly upload and share evidence with any stakeholder in an easy two-step process. The capability can significantly trim the investigative process from potentially weeks with traditional methods to mere minutes. Further leveraging "Smart Upload," forensic teams can also simultaneously load multiple, large files in one step. The new "Quick Share" permissions save additional crucial time by connecting new and existing stakeholders, securely and intuitively. "Quick Share" also allows for inter-agency sharing, where users across agencies can connect to the same portal.

08:43 EDT BYND Cannasoft files U.S. provisional patent, PCT application for EZ-G Device - BYND Cannasoft Enterprises announced today Zigi Carmel Initiatives & Investments, has filed a patent application for its AI based EZ-G device with the World Intellectual Property Office, also known as WIPO. The patent application listed as Publication Number WO/2023/13195 was published on the World Intellectual Property Organization's global database for intellectual property on July 13, 2023. The WIPO application specifically relates to adult toys utilizing one or more sensors for controllable operation and liquid administering mechanism. The next steps include substantive examination, followed by granting or refusing legal protection to the invention. According to its website, the World Intellectual Property Organization is the global forum for intellectual property services, policy, information and cooperation. It is a self-funding agency of the United Nations, with 193 member states.

08:40 EDT Globus Medical launches MARVEL Growing Rod System - Globus Medical announced the commercial launch of the MARVEL Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive distraction. MARVEL growing rods feature a powerful geared mechanism that provides reliable, efficient lengthening through a large 40mm or 60mm expansion range, with PEEK polymer bearing surfaces to minimize wear. Lengthening of each rod is achieved through a minimally invasive procedure with a small incision for driver access to minimize soft tissue disruption.

08:38 EDT Blink Charging appoints Aviv Hillo to board of directors - Blink Charging announced that Aviv Hillo, Esq., General Counsel and Executive Vice President of Mergers & Acquisitions, was elected to the Board of Directors at the Annual Shareholder's Meeting on July 24, 2023. Additionally, Ritsaart van Montfrans was elected Chair of the Board. Brendan Jones, Jack Levine, Kristina Peterson, Mahi Reddy, and Cedric Richmond were re-elected to serve another term on the Board of Directors.

08:37 EDT DSS announces distribution date for Impact Biomedical spin-off - DSS announced the distribution date for the previously announced stock dividend of Impact BioMedical Inc. DSS Inc. shareholders of record on July 10, 2023 will be entitled to four shares of Impact Biomedical Inc. for every one share of DSS to be distributed on August 8, 2023. Shares will be registered under CUSIP Number 45259L 106. Each share of Impact BioMedical distributed as part of the distribution will not be eligible for resale until 180 days from the date Impact BioMedical's initial public offering becomes effective under the Securities Act, subject to the discretion of the Company to lift the restriction sooner.

08:34 EDT Sypris Solutions gets order for Atoka Water project for Oklahoma City, no terms - Sypris Technologies , a subsidiary of Sypris Solutions announced that it has recently received an order to supply 72-inch Insulated Joints for use in the expansion of the Atoka Water Pipeline for the Oklahoma City Water Utilities Trust. Shipments under this award are expected to start in 2023 and finish in 2024. Terms of the order were not disclosed. ..Sypris has agreed to manufacture and supply its Tube Turns-branded monolithic Insulated Joints for cathodic protection of the new 72-inch polyethylene-coated and cement-mortar lined steel pipeline. These Insulated Joints will be 72 inches in diameter and will be rated to a pressure of 300 psi. Brett Keener, General Manager, commented, "Sypris continues to be a leader in supplying engineered products to support major infrastructure projects globally. By leveraging our extensive engineering design and manufacturing expertise, we believe we are uniquely qualified to support these types of demanding projects. We are proud to be a part of a project with a goal of providing reliable water infrastructure which is essential to public health and our way of life."

08:32 EDT IperionX receives all permits to commence construction at Virginia facility - IperionX has received all permits required to commence construction and operations at the planned titanium metal production facility in Virginia. These permits include the Industrial Wastewater Discharge permit issued by the Halifax County Service Authority, and the New Source Review permit issued by the Virginia Department of Environmental Quality. These permits meet the requirements to scale to the planned TCF-1 capacity of 1,125 tpa of titanium metal within the existing 50,000 square foot shell building in Halifax County, Virginia. All major engineering works for the planned Stage 1 TDF are now complete, with key long lead time equipment ordered and procurement underway. First titanium production is planned for Q1 2024, and IperionX plans to reach a production run-rate of 125 tpa of titanium metal by Q3 2024. A planned modular Stage 2 expansion to the TCF-1 level would lift titanium production capacity to 1,125 tpa by the end of 2025. Development of the TDF remains subject to Board approval for a final investment decision. The design of the TDF and TCF-1 are based upon a scaled-up version of the current Industrial Pilot Facility, in Salt Lake City, which has been successfully operated by IperionX since January 2022. IperionX has upgraded this facility, and improved operational processes, to achieve a significant increase in the titanium production capacity with higher efficiency and consistency. IperionX now plans to build the largest recycled titanium metal powder production facility globally, and the only titanium plant that uses 100% titanium scrap metal as feedstock. The titanium production facility in Virginia is designed to have zero Scope 1 & 2 emissions and is expected to produce UL validated 100% recycled titanium metal powder with the lowest carbon intensity on the market. The Halifax County Development Authority will fund the building fit-out works with an investment of up to US$4m to prepare for process equipment installation in late 2023.

08:31 EDT TC Biopharm regains Nasdaq compliance - TC BioPharm announced that the company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the company's American depositary shares on the Nasdaq Global Select Market.

08:26 EDT Shoals Technologies announces commercial availability of Snapshot I-V solutions - Shoals Technologies Group announced its patent pending Snapshot I-V solar PV health monitoring solutions. Shoals' Snapshot I-V is an ecosystem of products that integrate seamlessly into a solar asset management system. The solution remotely monitors the health and performance of their PV modules over the life of the system. PV modules represent the largest single investment in a solar system, and accurate and timely performance monitoring is essential to take action in case of PV module underperformance. The first commercially available solutions in the Snapshot I-V family will be Snapshot I-V Wireless Meter and Snapshot I-V Wireless Gateway.

08:23 EDT Amarin, Lotus Pharmaceuticals partner to commercialize Vazkepa in Southeast Asia - Amarin Corporation (AMRN) and Lotus Pharmaceuticals (LTUS) announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA across 10 countries, including nine in Southeast Asia and South Korea. VAZKEPA capsules have been approved and commercialized in a number of global markets, including the U.S. and European markets, as the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid. Under the terms of the agreement, Lotus will have exclusive rights to distribution and commercial promotion for VAZKEPA in South Korea and nine countries in ASEAN: Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. As part of the agreement, Amarin will receive an upfront payment as well as pricing and reimbursement and sales milestone payments based on net sales of the product. Amarin will be responsible for supplying finished product to Lotus at a pre-defined supply price.

08:20 EDT Enlivex doses first patient under amended protocol of Phase II trial - Enlivex Therapeutics announced that the first patient has been dosed under the amended protocol for the Company's Phase II trial evaluating Allocetra in patients with sepsis. As previously announced, the amended protocol allows a higher SOFA score inclusion range, which allows the recruitment of patients with higher levels of sepsis severity. Additionally, the amended protocol provides for two cohorts rather than the prior protocol's four-cohort structure.

08:19 EDT Immutep to present overall survival data from TACTI-002 Phase II trial - Immutep Limited announces that data from its TACTI-002 Phase II trial evaluating the chemo-free combination of eftilagimod alpha and KEYTRUDA in 1st line non-small cell lung cancer has been accepted for a Mini Oral presentation at the 2023 European Society for Medical Oncology Congress that will be held in Madrid, Spain from 20-24 October 2023. The presentation will include more mature overall survival data, following on from the data announced on 17 May 2023. Additionally, data from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF evaluating efti in conjunction with anti-PD-1 therapy and doublet chemotherapy in non-squamous 1L NSCLC, has been accepted for a poster presentation. Also, a Trial in Progress poster for the EFTISARC-NEO investigator-initiated Phase II trial evaluating efti with pembrolizumab and radiotherapy in soft tissue sarcoma will be presented.

08:16 EDT Aemetis closes $25M financing to fund digesters for eight dairies - Aemetis announced the closing of its second $25 million, 20-year term loan guaranteed by the U.S. Department of Agriculture for a total of $50 million of Aemetis Biogas project financing arranged by Greater Commercial Lending in the past nine months. The Aemetis Biogas Central Dairy RNG Project is now fully funded to build biogas digesters and related assets for eight additional dairies using the $9.4 million of equity financing already provided by Aemetis and the $25 million of new debt financing guaranteed by the USDA. Magnolia Bank of Elizabethtown, Kentucky provided the primary funding for the $25 million loan to Aemetis Biogas 2, a wholly-owned subsidiary of Aemetis, Inc. Aemetis Biogas has built and is fully operating dairy biogas digesters for seven dairies, a 40-mile biogas pipeline, the central biogas-to-RNG production facility and the PG&E gas utility interconnection unit. When completed, the biogas digesters for the combined 15 dairies are designed to produce more than 400,000 MMBtus per year of carbon negative renewable natural gas. The long-term, 20-year project financing was guaranteed by the USDA through the Rural Energy for America Program (REAP) and carries approximately an 8.75% fixed interest rate for the first five years. With two REAP loans closed and three more REAP loans in process, Aemetis Biogas is currently arranging $125 million of 20-year debt funding for the development, construction and operation of the Aemetis Central Dairy Digester project which has already signed 37 dairies and plans to build digesters for 65 dairies within the next 60 months.

08:14 EDT RMR Group acquires CARROLL for $80M cash, expected to be immediately accretive - The RMR Group announced that it has entered into a definitive agreement to acquire 100% of the equity interests in MPC Partnership Holdings doing business as CARROLL a vertically integrated multifamily platform, in an all cash transaction for $80M subject to customary purchase price adjustments, with the potential for incremental earnout . The acquisition of CARROLL represents the successful advancement of RMR's strategic plan to expand its private capital business and utilize its balance sheet to diversify into additional real estate sectors. The transaction advances the following objectives..Enhances RMR's position as a leading alternative asset management platform, growing total AUM to approximately $44 billion and private capital AUM to approximately $15B. Positions RMR for continued growth, including through the ability of CARROLL's general partner fund series to make in excess of $3 billion of additional multifamily investments. Value Creation Expected to be immediately accretive to Adjusted EBITDA, Adjusted EPS and Distributable Earnings per share. Provides RMR with a proven fund platform to generate performance-based promote fees on new co-investments.

08:11 EDT Taysha Gene Therapies says IDMC recommends continuation of REVEAL trial - Taysha Gene Therapies announced that the Independent Data Monitoring Committee recommended the continuation of the REVEAL Phase 1/2 trial and that dosing of the second patient in the first cohort can proceed. The decision follows a pre-specified IDMC review of initial clinical data from the first patient dosed with TSHA-102 following the 42-day evaluation period. The REVEAL Phase 1/2 trial is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in adult females with Rett syndrome due to MECP2 loss-of-function mutation. TSHA-102 is administered as a single lumbar intrathecal injection. Dose escalation will evaluate two dose levels of TSHA-102 sequentially. The maximum tolerated dose or maximum administered dose established will then be administered during dose expansion.

08:08 EDT Bionano Genomics announces OGM roadshow, TOUR - Bionano Genomics announced the launch of its optical genome mapping roadshow, Bionano TOUR, a series of regional customer-led events that showcase the latest advancements to the OGM workflow and demonstrate applicable research applications. Bionano TOUR provides an immersive in-person experience for attendees, combining informative demonstrations of the OGM workflow, the Ionic system and VIA software from internal Bionano experts with presentations from current OGM users who have implemented the workflow for research in hematological malignancies, genetic disease, cell bioprocessing, and other applications. By bringing together industry experts, thought leaders, and technical product specialists, the event serves as a platform for attendees to explore ways OGM might provide new cytogenetic insights in their research and address critical gaps that are left unanswered by other genome analysis products. Moreover, TOUR acts as a catalyst for building strong, locally supported OGM communities, allowing users to connect with their peers and helping to build relationships amongst current and potential customers.

08:07 EDT Axial3D receives FDA clearance for Axial3D INSIGHT platform - Axial3D announced "that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications. This achievement is the second FDA clearance Axial3D has received for its segmentation platform, INSIGHT and a significant milestone for the healthcare industry in its embrace of automation and artificial intelligence to personalize patient care. The FDA clearance is expected to provide a major boost towards scaling up production processes particularly by medical device companies. Our FDA clearance for Axial3D INSIGHT is a testament to how far Axial3D has come," stated Dan Crawford, Founder and CSO of Axial3D. "From our humble beginnings as a startup to now being recognized as a leading medical technology company, this achievement showcases our dedication to pushing the boundaries of innovation in healthcare. We are immensely proud of our team's commitment in delivering exceptional patient care using advanced automation, artificial intelligence, and machine learning technologies." Stratasys Ltd. ( SSYS) led an investment round in late 2022 to help advance Axial3D's technology and to bring a joint solution to market for healthcare providers and medical device manufacturers. "Stratasys is proud to partner with Axial3D in driving innovation and in transforming the healthcare landscape with 3D solutions that help make personalized healthcare at scale possible," said Stratasys CEO Dr. Yoav Zeif. "We congratulate Axial3D on achieving FDA clearance for their segmentation platform, leveraging the power of automation and AI as a key business driver for their continued success in the medical sector." "

08:06 EDT Apollo Medical announces partnership with IntraCare - Apollo Medical Holdings announced an agreement to partner with IntraCare, an operator of a value-based primary care provider network and primary care clinics located predominantly in Texas with a growing presence in Oklahoma. ApolloMed's partnership with IntraCare is poised to accelerate access to high-quality, value-based care for seniors in three areas. First, ApolloMed's ACO will partner with IntraCare's primary care providers as part of the ACO REACH program, an attribution-based risk-bearing model designed to advance health equity and bring the benefits of accountable care to Medicare beneficiaries in underserved communities. In addition, ApolloMed will deploy its value-based care platform as the exclusive care enablement partner for IntraCare providers participating in the ACO REACH program. Finally, to further IntraCare's mission and growth, ApolloMed will lend IntraCare a $25M senior secured convertible promissory note maturing in 2028. Guggenheim Securities, LLC acted as financial advisor to IntraCare in connection with the transactions.

08:04 EDT Jet.AI launches CharterGPT AI-powered booking application - Jet.AI announced the launch of its AI-powered charter booking application, CharterGPT. This cutting-edge technology automates the manual process of booking a private jet. Through natural language processing, the CharterGPT app communicates with both consumers and charter operators to reduce the time spent by a broker as the "human-in-the-loop." Of roughly 2,350 Part 135 charter operators in the US, 80% currently have fewer than ten aircraft and 60% have fewer than five. These Part 135 charter operators function as something akin to miniature airlines and can be hard to get a charter quote from. Aside from handling customer conversations, CharterGPT is designed to help weed through, and obtain responses from, these smaller operators via outbound, interactive, natural language communication. The next iteration of the app due in the fall is also expected to integrate with Stripe for payments, support automatic contract reconciliation between Jet.AI's contracts with customers and contracts with operators, provide recommendations on preferred ground transportation, most efficient airport locations to travel in and out of, most opportune departure dates and more. The CharterGPT app has been uploaded to the iOS store and is planned for release in early August with Android store release expected a few weeks later.

08:02 EDT BioNTech completes acquisition of InstaDeep - BioNTech announced the completion of the acquisition of InstaDeep. The acquisition was announced on January 10, 2023 and follows a track record of increasing collaboration between the two companies since 2019 as well as BioNTech's initial equity investment as part of InstaDeep's Series B financing round in January 2022. The acquisition supports BioNTech's strategy, aiming to build world-leading capabilities in AI-driven drug discovery and development of next-generation immunotherapies and vaccines to address diseases with high unmet medical need. InstaDeep will operate as a UK-based global subsidiary of BioNTech. In addition to BioNTech-focused projects, InstaDeep will continue to provide its services to clients around the world in diverse industries, including in the Technology, Transport & Logistics, Industrial, and Financial Services sectors. The transaction adds approximately 290 highly skilled professionals to BioNTech's workforce, including teams in AI, ML, bioengineering, data science, and software development. The total consideration to acquire the remaining InstaDeep shares, excluding the shares already owned by BioNTech, amounts to approximately EUR 500 million in cash, BioNTech shares, and performance-based future milestone payments.

08:00 EDT 60 Degrees Pharmaceuticals awarded Canadian patent for tafenoquine - 60 Degrees Pharmaceuticals announced that the Canadian Intellectual Property Office has issued the Company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals. Travelers from, and residents of, Canada and the United States, are usually malaria naive because they have not previously contracted malaria and thus lack immunity to the disease. Tafenoquine is the active molecule in the Company's U.S. Food and Drug Administration-approved regimen for malaria prevention, ARAKODA. ARAKODA, an oral tablet containing 100 mg of tafenoquine base, is an anti-malarial indicated in the U.S. for the prophylaxis of malaria in individuals aged 18 years and older. Travelers or individuals at risk of contracting malaria are prescribed 2 x 100 mg tablets once per day for three days prior to travel, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. ARAKODA is not approved by Health Canada for the prevention of malaria. The newly issued Canadian patent provides exclusive use of tafenoquine for preventing malaria in malaria-naive patients in Canada to December 2, 2035. The Company was previously issued a U.S. patent covering the use of tafenoquine for malaria prevention in malaria-naive individuals. The U.S. and Canadian patents cover the ARAKODA dosing regimen approved in the U.S. for malaria prevention.

07:55 EDT Alterity Therapeutics reports cash balance of A$15.8M as of June 30 - "The last several months have been extremely productive for Alterity as we hit several milestones and made significant progress advancing ATH434," said David Stamler, M.D., CEO. "With the clearance by the Data Monitoring Committee to continue the ATH434-201 trial as planned and the enthusiasm for the trial from physicians around the world, the trial remains on track to complete enrollment in the third quarter of 2023 with top-line data expected by the end of 2024. We also initiated a second Phase 2 study, ATH434-202, in participants with more advanced MSA. Importantly, this Biomarker study gives us the opportunity to get an early indication of efficacy before the ATH434-201 Phase 2 study reads out. Individuals with more advanced MSA may also benefit from ATH434 and measuring key biomarkers will permit us to evaluate drug activity in this population. The data derived from the Biomarker study have the potential to accelerate the overall development program. An important element of our ATH434-201 trial is the use of wearable sensors to determine the impact of ATH434 on motor impairment and gait stability. During the quarter, data from the bioMUSE natural history study reinforced this measure by showing that wearable sensors can be used to assess disease progression that may not be captured by neurological examination. The Company's cash position on 30 June 2023 was A$15.8M with operating cash outflows for the quarter of A$6.2M. The company anticipates the cash position will be boosted in the coming weeks with the receipt of the A$4.7M R&D Tax incentive for the 2022 fiscal year.

07:35 EDT Chart Industries celebrates 'Teddy 2' facility construction progress - Chart Industries celebrates its "Teddy 2" facility construction progress, named as such because it is Chart's second facility in Theodore, Alabama. This plant is expected to fabricate the largest shop-built cryogenic tanks ever manufactured globally - 70% larger than the previous largest with manufacturing production set to begin in the first quarter 2024. The tanks manufactured at this site will be used for propellant storage for the aerospace industry, hydrogen and LNG storage for the marine industry, and many other processes and technologies in the sciences and decarbonization industries. Teddy 2's easy access to waterways will provide additional opportunities for our customers to have lower cost, faster freight and transportation to site. In addition to the ability to manufacture to this scale, this expansion also contributes significantly to local job creation and economic development efforts for the state of Alabama. We have expectations that our Teddy 2 facility will achieve annual revenues in excess of $175 million. This also benefits local subcontractors in Alabama for process that we outsource, including the $7.2 million of improvements to the onsite wharf which were awarded in full to local businesses. Teddy 2 is anticipated to employ over 90 people across two shifts as we continue to receive orders for these applications. Chart began construction of this greenfield 127,000 square foot facility in Theodore, Alabama in early April 2023, and it is due to complete in April of 2024.

07:34 EDT Carnival announces anticipated debt pre-payment of $1.2B - Carnival announced that it intends to commence the marketing of a new senior secured first lien term loan B facility with an original principal amount of $1B, expected to mature in 2027. In conjunction with the New First Lien Term Loan, and subject to market and other conditions, the company may raise $500M of other secured debt maturing in 2029. The company intends to use the proceeds from the Refinancing Transactions to repay a portion of the borrowings under the company's existing first-priority senior secured term loan facility maturing in 2025. After the closing of the Refinancing Transactions, the company intends to redeem all of the company's 10.500% second-priority senior secured notes due 2026 and 10.125% second-priority senior secured notes due 2026, saving over $120M in interest expense on an annualized basis. The $1.2B of redemptions will be conditioned on the closing of the Refinancing Transactions. The company expects to use cash on hand to finance the redemptions. The company's CFO David Bernstein commented: "Given the confidence we have in our business and its cash flow generation, we plan to retire $1.2 billion of our highest cost debt. In connection with this retirement, we plan to extend some of the lowest cost public debt in our portfolio. This is yet another step forward in our deleveraging journey, building on the $1.4 billion we already early retired this year. With this debt repayment, we now expect our year end debt balance to be less than $32.0 billion, an improvement over the November 30, 2023 debt balance of less than $33.0 billion provided in our June guidance."

07:32 EDT BridgeBio announces opportunity for accelerated approval pathway in LGMD2I/R9 - BridgeBio Pharma announced that, based on discussions with the U.S. Food and Drug Administration, there is a potential path to pursue accelerated approval in the U.S. for BBP-418, an investigational oral substrate supplementation therapy, in patients with limb-girdle muscular dystrophy type 2I. BridgeBio also announced that the first patient with LGMD2I/R9 has been dosed in its Phase 3 FORTIFY clinical trial of BBP-418. To date, the Company has activated over half the planned U.S. clinical sites and is in the process of opening sites in Europe and Australia to support global registration. The Phase 3 FORTIFY registrational study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BBP-418. FORTIFY has a planned interim analysis at 12 months focused on assessing glycosylated alphaDG as a surrogate endpoint to potentially support an accelerated approval. The North Star Assessment for Dysferlinopathy and secondary endpoints will be evaluated at 36 months, and results are expected to provide confirmatory clinical data. A novel, validated bioassay was developed by BridgeBio to directly measure glycosylated DG levels, which are central to LGMD2I/R9 disease, and may enable monitoring of responses to disease-modifying therapies in LGMD2I/R9 patients. BridgeBio is committed to collaborating with the FDA to address the challenges associated with LGMD2I/R9 drug development, including the potential use of a surrogate endpoint to support an accelerated approval. BBP-418 is designed to supply supraphysiological levels of an endogenous substrate upstream of the mutant FKRP enzyme to help drive residual activity of the enzyme to glycosylate alphaDG, with the goal of stabilizing muscle cells during contraction, and potentially halting further muscle damage. Data from an ongoing open-label Phase 2 study is consistent and encouraging, suggesting that BBP-418 may be well-tolerated and have a positive impact on key endpoints. Updated results on the Company's novel bioassay and for the Phase 2 clinical trial will be presented at the Annual Congress of the World Muscle Society, taking place in Charleston, South Carolina on October 3 - 7, 2023. If approved, BridgeBio believes BBP-418 could be the first approved orally administered therapy for the treatment of patients with LGMD2I/R9.

07:23 EDT Clearside Biomedical presents safety, tolerability data from OASIS trial - Clearside Biomedical announced that safety and tolerability data from its recent OASIS clinical trial of CLS-AX were presented at the American Society of Retina Specialists 41st Annual Scientific Meeting. CLS-AX is a proprietary suspension formulation of the tyrosine kinase inhibitor axitinib that provides high potency pan-VEGF inhibition delivered via Clearside's proprietary SCS Microinjector. The presentation, entitled, "Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy" was delivered by Rahul N. Khurana, MD, FACRS, Northern California Retina Vitreous Associates. Dr. Khurana presented data from Clearside's OASIS Phase 1/2a clinical trial and Extension Study highlighting the excellent safety profile with no serious adverse events, no adverse events from inflammation, no vasculitis or vascular occlusion, and no treatment emergent adverse events related to study treatment. The presentation described the promising results from the 6-Month Extension Study at higher doses in Cohort 3 and Cohort 4. These cohorts showed signs of durability and a 77% - 85% reduction in treatment burden. Additionally, signs of biologic effect with stable mean best corrected visual acuity and stable mean central subfield thickness to the 6-month timepoint were seen in these cohorts. OASIS was an open-label, single dose-escalation Phase 1/2a trial in neovascular age-related macular degeneration. OASIS was a 3-month trial, followed by a 3-month Extension Study. The trial included four cohorts at the following doses: Cohort 1 at 0.03 mg; Cohort 2 at 0.1 mg; Cohort 3 at 0.5 mg; Cohort 4 at 1.0 mg. Participants from Cohorts 2, 3 and 4 who rolled over into the Extension Study were followed for a total of 6 months after a single dose of CLS-AX. Participants enrolled in OASIS were heavily anti-VEGF treatment experienced with active disease at screening, which was confirmed by an independent reading center.

07:19 EDT Alliance Resource lowers coal production and sales volume guidance for 2023 - "The recent heat wave has supported additional coal burn this summer for both the domestic and export markets. However, until Henry Hub natural gas prices rise above $3 per million Btu, we do not expect any meaningful gas-to-coal switching domestically. Therefore, we have chosen to reduce our coal production and sales volume guidance for 2023. Production targets have been reduced at our River View and Gibson operations in the Illinois Basin and at our Mettiki operation in Appalachia," commented Mr. Craft. "Committed and priced sales tons currently represent 96% to 97% of our updated guidance range, and we plan to sell any remaining uncontracted tonnage primarily into international markets from these three mines. We have also adjusted the top end of our coal sales price per ton sold range downward based upon recent market analysis. On the positive side, we are lowering our cost estimates for the year as our team continues to find ways to reduce expenses in a stubbornly volatile inflationary environment." Craft added, "During the 2023 Quarter, we agreed to sell an additional 8.6 million tons with multiple customers for coal to be delivered over the 2024 to 2026 time period. We expect there will be more opportunities this year to fill out our future contract book." Mr. Craft closed, "These modest guidance revisions have not changed our view that we remain on track to achieve record financial results this year. As we look beyond 2023, we are encouraged by growth opportunities being pursued by our New Ventures group, the recent increase in the forward oil and gas price curves and acquisition prospects for our Oil & Gas Royalties segment. We are also seeing stability for coal demand over the next several years. Many of our coal customers are projecting significant growth in electricity demand as record numbers of new manufacturing facilities are being announced to come online over the next several years. All of these announced projects require exceptionally large electrical loads, adding to the reliability concerns of the stakeholders responsible for meeting the rising energy needs of their customers. The increased electricity demand should lead to slowing the pre-mature closing of coal-fired power plants in the eastern United States. We also expect the growth in LNG terminals coming online over the next five years will support higher domestic natural gas prices further supporting stable demand expectations for our coal operations over the next five to ten years."

07:14 EDT Alliance Resource Partners sees FY23 coal volumes 25M - 25.25M short tons - Sees FY23 coal total sales tons 35.50 - 36M total slaes tons.

07:13 EDT Universal Stainless & Alloy announces base price increase on bar products - Universal Stainless & Alloy Products announced a base price increase of 5% to 10% on bar products. The increase goes into effect immediately. Current material and energy surcharges will remain in effect.

07:11 EDT Quest Diagnostics announces availability of the AD-Detect on questhealth - Quest Diagnostics announced the availability of the AD-Detect Test for Alzheimer's Disease on questhealth.com - the first blood test available for consumer purchase that helps assess potential risk of developing Alzheimer's disease based on a brain protein that contributes to the condition. AD-Detect is a screening test that uses plasma, the liquid component of blood, from a single blood draw to evaluate levels of amyloid beta proteins to help detect early signs associated with the risk of developing Alzheimer's disease. Amyloid beta proteins are known to accumulate and form plaques in the brain, which are linked to the progression of Alzheimer's disease. AD-Detect evaluates the ratio of two peptides of amyloid beta, Abeta42 and Abeta40, in plasma. The new test from Quest may be appropriate for individuals who believe they are experiencing cognitive decline or if an individual's loved one recognizes potential signs of mild cognitive impairment, such as memory loss, as well as those with family history of Alzheimer's disease - even if they are not exhibiting symptoms, are 65 years of age or older, or have had brain trauma or head injury.

07:09 EDT TFF Pharmaceuticals, Uniphar Durbin open EAP for TFF VORI - Uniphar Durbin Ireland and TFF Pharmaceuticals announced the opening of an Expanded Access Program enabling patients access to TFF-VORI in the United States, Australia, United Kingdom, Canada and select countries in Europe.

07:07 EDT Cyclerion Therapeutics, Tisento close asset purchase agreement - Cyclerion Therapeutics and Tisento Therapeutics announced the closing of the previously disclosed asset purchase agreement. Tisento is launching with an $81M Series A financing to support its development of the Phase 2 soluble guanylate cyclase stimulator zagociguat in MELAS and other genetic mitochondrial diseases, as well as the company's advancement of additional assets for serious diseases with unmet need. Zagociguat is a first-in-class, brain-penetrant sGC stimulator that modulates the nitric oxide-cyclic guanosine monophosphate pathway, a fundamental cell-signaling pathway, and has shown potential to treat both central nervous system and peripheral symptoms of mitochondrial diseases. Phase 2a clinical data, generated by Cyclerion, showed rapid improvements in disease-associated biomarkers in patients with MELAS who received zagociguat for 28 days. In the study, zagociguat exhibited an excellent safety profile, exposure in the CNS and throughout the body consistent with once-daily oral dosing, and improvements across key domains of the disease pathophysiology including neuronal function, mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. Major Cyclerion shareholders participated in Tisento's Series A financing, including Invus, Peter Hecht, Polaris, and others. They are joined in the Tisento investor syndicate by Sanofi Ventures, Venrock, J. Wood Capital, and others. In the transaction, Tisento acquired from Cyclerion zagociguat and CY3018, a CNS-targeted sGC stimulator in IND-enabling studies. Cyclerion received 10 percent equity ownership in Tisento with anti-dilution protection through $100 million in post-money valuation, as well as the right to purchase additional Tisento equity in the future. The Tisento equity ownership provides Cyclerion shareholders with the opportunity to benefit from future Tisento value creation without further financial or operational obligations for the Tisento assets. In addition, Cyclerion received a $10.4 million cash payment, consisting of an $8 million upfront payment and reimbursement for certain employee and development expenses related to zagociguat and CY3018 for the period between the signing and closing of the transaction. In conjunction with the asset sale, Peter Hecht invested $5 million in Cyclerion.

07:06 EDT EC approves Marinus Pharmaceuticals' Ztalmy for epelctic seizures from CDD - Marinus Pharmaceuticals announced that the European Commission EC has granted approval of ZTALMY or ganaxolone oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 CDKL5 deficiency disorder CDD in patients two to 17 years of age. ZTALMY may be continued in patients 18 years of age and older. "The approval by the European Commission represents a significant milestone for children, families and physicians who, until now, have long been challenged by the impact of seizures and lack of treatments available for CDD," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "This achievement reflects our organization's unwavering commitment to bring an effective treatment option to individuals living with CDD and we are grateful to all the stakeholders who made the approval possible." The EC approval of ZTALMY in CDD is supported by data from the Phase 3 Marigold double-blind placebo-controlled trial, in which 101 patients were randomized and individuals treated with ZTALMY showed a median 30.7% reduction in 28-day major motor seizure frequency, compared to a median 6.9% reduction for those receiving placebo, achieving the trial's primary endpoint . In the Marigold open label extension study, patients treated with ZTALMY for at least 12 months experienced a median 49.6% reduction in major motor seizure frequency. In the clinical development program, ZTALMY demonstrated efficacy, safety and tolerability with the most common adverse reactions in the ZTALMY group being somnolence, pyrexia, salivary hypersecretion and seasonal allergy. In May 2022, the results from the Marigold study were published in The Lancet Neurology.1 The approval follows a positive opinion issued in May 2023 by the Committee for Medicinal Products for Human Use of the European Medicines Agency and is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. In July 2021, Marinus and Orion Corporation entered into a collaboration agreement which grants Orion the right to commercialize ZTALMY in Europe.

07:03 EDT Taoping announces 1-for-10 reverse stock split - Taoping announced that the board of directors of the company approved a one-for-ten reverse stock split of the company's issued and outstanding ordinary shares, no par value. Beginning August 1, the company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.

07:02 EDT RedHill Biopharma: RHB-107 included in Government-supported COVID-19 trial - RedHill Biopharma announced that RHB-107 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funded by the U.S. Government Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, has received FDA clearance to start and is estimated to be completed by end of 2024.

06:53 EDT Endeavour Silver to sell 1% stake in Cozamin Royalty to Gold royalty for $7.5M - Endeavour Silver (EXK) is pleased to announce that its wholly-owned subsidiary, Minera Plata Adelante SA de CV, has entered into an agreement with Gold Royalty (GROY) to sell all of MPA's interest in the 1% Cozamin royalty for total consideration of $7.M, payable in cash. The Royalty applies to two concessions (Calicanto and Vicochea) on Capstone's Cozamin copper-silver mine, located 3.6 kilometres north-northwest of Zacatecas City in state of Zacatecas, Mexico. The company obtained the Royalty through a concession division agreement signed in 2017 on seven wholly owned concessions which were acquired for $445,000 The Cozamin Mine, a copper-silver mine owned and operated by Capstone Copper in Zacatecas, Mexico, is located on two of the seven Concessions. The sale agreement includes an option granted to Gold Royalty Corp to purchase any additional royalties which may be granted on the five remaining concessions under the 2017 concession division agreement. The definitive agreement is subject to standard closing conditions and is expected to be completed by August 31, 2023.

06:36 EDT ImmunoGen announces departure of Chief Medical Officer Anna Berkenblit - ImmunoGen announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen. Dr. Berkenblit will continue with the company through the end of August to support the transition of her responsibilities. Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer.

06:34 EDT Ceragon Networks names Ilan Rosen as chairman - Ceragon Networks announced that the board of directors named Ilan Rosen, a member of the board of directors since July 2021, as its new chairman. Rosen succeeds Zohar Zisapel, who sadly passed away on May 19. Rosen has expertise in concluding mergers and acquisitions, deploying value-creation strategies, and enhancing corporate governance.

06:32 EDT Pan American Silver announces divestment of MARA - Pan American Silver is pleased to announce the status of our divestment of certain non-core assets, including the sale of our interest in the MARA project in Argentina, the Morococha mine in Peru, and the Agua de la Falda project in Chile. "The sale of these non-core assets is aligned with our stated aim of optimizing our portfolio following the Yamana acquisition. These transactions not only reaffirm our commitment to our core business but also yield substantial and immediate value to our shareholders, while maintaining future upside through the retention of copper and gold royalties with strong counterparties," said Michael Steinmann, President and CEO of Pan American. "The consideration for the sale of MARA, coupled with the other sales, will yield total cash proceeds of US$593 million. The cash proceeds will allow us to both fully repay the amount drawn on our credit facility and increase our cash position, further enhancing the resilience of our balance sheet. These transactions will also allow Pan American to reduce its annual project development, reclamation and care and maintenance costs, which for MARA and Morococha amounted to $15.7 million in Q2 2023. This improved balance sheet strength creates enhanced opportunities for the company, providing increased capital to advance key strategic projects, including the La Colorada Skarn Project."

06:08 EDT Emeren sells 11.5 MWp PV project to MET Group, terms undisclosed - Emeren Group announced the sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren. The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.

06:05 EDT Allarity and FivepHusion announce collaboration agreement for Deflexifol - Allarity Therapeutics and Detsamma Investments, trading as "FivepHusion," an advanced clinical-stage biotechnology company developing Deflexifol, announced that the two companies have entered into a Clinical Collaboration Agreement. Under this agreement, Allarity will support FivepHusion's future clinical development of Deflexifol for the treatment of solid tumors by using certain of Allarity's drug-specific DRP companion diagnostics, including its validated DRP-5FU companion diagnostic, to potentially select patients for enrollment and treatment in clinical trials of Deflexifol as a monotherapy and in combination with other drugs. Deflexifol is a novel anti-cancer drug reformulation designed to address the safety and efficacy limitations of standard-of-care 5FU chemotherapy. It combines, in a single infusion, 5FU and LV, a drug that potentiates 5FU anti-tumor activity, to improve the therapeutic activity of 5FU. FivepHusion expects to start a phase 1b/2a study investigating Deflexifol in combination with oxaliplatin, or DEFLOX, and bevacizumab in the 1st line treatment of unresectable metastatic colorectal cancer, or mCRC, patients in H2 2023. Under the terms of the Clinical Collaboration Agreement, Allarity will initially support FivepHusion's planned Phase 1b/2a trial of DEFLOX plus bevacizumab in 1st line treatment of unresectable mCRC, which will be conducted at trial sites in Australia. Allarity will receive patient biopsies from the trial and analyze them using the DRP companion diagnostics technology to identify patients most likely to respond or not respond to the DEFLOX plus bevacizumab regimen. Following conclusion of the Phase 1b/2a study, FivepHusion will determine whether the ability of the DRP companion diagnostics technology to select patients responsive to DEFLOX plus bevacizumab and/or Deflexifol monotherapy warrants prospective use of the companion diagnostic to select and enroll mCRC patients, in an international, Phase 3 registration study for the drug. Financial terms of the clinical collaboration, option and potential license are not disclosed.

05:25 EDT Flutter Entertainment, Fox Corp. announce close of Fox Bet - Flutter Entertainment (PDYPY) and Fox Corp. (FOX) announced the decision to close sports betting platform Fox Bet. A phased closure of Fox Bet's operations will take place between July 31 and August 31. Flutter operated Fox Bet as part of The Stars Group US along with the U.S. facing operations of PokerStars. Flutter will retain ownership of PokerStars, in addition to US sports betting market leader FanDuel. Fox will retain future use of the Fox and Fox Bet brands, including FOX Bet Super 6, and intends to launch an all-new FOX Super 6 game later this summer. Fox will continue to hold its option to acquire 18.6% of FanDuel and in addition holds a 2.5% stake in Flutter.

05:21 EDT Manchester United renews principal partnership with Adidas - Manchester United (MANU) confirmed that it has renewed its principal partnership with Adidas (ADDYY), as the club's official kit supplier. The new agreement will continue the partnership for a further 10 years until June 2035 and has a minimum cash guarantee of GBP 900M, subject to certain adjustments.

05:17 EDT Archer Aviation signs $142M in contracts with DoD - Archer Aviation announced that it has significantly expanded its partnership with the DoD by signing new contracts with the U.S. Air Force with a total value of up to $142M. The new contracts signal the U.S. military's recognition of the transformative potential Archer's innovative eVTOL aircraft brings to our country's Armed Forces. This new execution phase of the partnership includes the delivery of up to six of Archer's Midnight aircraft to the Air Force, the sharing of additional flight test data and certification related test reports, pilot training, and the development of maintenance and repair operations. As a result of these contracts, Archer will create and provide innovative capabilities that will strengthen the national defense of the United States of America.